- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.09. | Advanz Pharma's bid to keep Ocaliva on EU market fails | ||
| 03.09. | 3D-printed tumours could aid cancer therapy R&D | ||
| 03.09. | Data builds behind Valneva, Pfizer's Lyme disease vaccine | ||
| 03.09. | Digital NHS health checks will start in England next year | ||
| 03.09. | As mpox cases rise over 18,000, UNICEF tenders for vaccines | ||
| 02.09. | BIA sends message to UK chancellor on R&D tax credits | ||
| 02.09. | iRhythm wearable heart monitor raises AFib diagnoses by 52% | ||
| 02.09. | Two of three trials fail, but Sanofi will still file MS drug | ||
| 02.09. | Kerendia works in heart failure, but how might it be used? | ||
| 30.08. | Emergent Bio gets FDA green light for mpox vaccine | ||
| 30.08. | UK biotech ReNeuron quits AIM as financing push fails | ||
| 30.08. | BioMarin's change in direction claims more jobs | ||
| 30.08. | J&J launches gMG market bid with nipocalimab filing | ||
| 30.08. | Bayer takes lung cancer therapy hope into phase 3 | ||
| 29.08. | GSK gets EU okay for RSV shot in younger age group | ||
| 29.08. | Women's health DTx developer Curio raises funds for PPD app | ||
| 29.08. | Push for self-injected drugs prompts Novartis/Lindy alliance | ||
| 29.08. | Neurocrine slides as schizophrenia data disappoints | ||
| 29.08. | Details emerge of £400m investment programme tied to VPAG | ||
| 28.08. | Novartis builds case for Leqvio with monotherapy data | ||
| 28.08. | MSD starts second phase 3 of Imago drug for blood cancers | ||
| 28.08. | Lilly launches single-dose Zepbound to ease self-pay access | ||
| 28.08. | AI voice assistant can spot complications in heart patients | ||
| 27.08. | Pfizer joins Lilly in direct-to-consumer drive | ||
| 27.08. | EU approves first therapy for acanthamoeba keratitis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
